OakChart

Belite Bio Inc ADR

BLTEHealthcare·Biotechnology·USA·Mid·NASD·Nov 11 • 3:59 PM ET

155.94-0.58 (-0.37%)
2026-11-12 03:56 CET
Market cap
6,280.03 USD m
Revenue, TTM
0.00 USD m
Net income, TTM
-102.36 USD m
Free cash flow, TTM
- USD m
EPS diluted, TTM
-2.73
P/E
-
Compare

Price

BLTE against its 20, 50 and 200-day averages
2050200beatmissearnings
140.00160.00180.00200.00369K739KVolumeMay 26Jun 26Jul 26Aug 26Sep 26Oct 26Nov 26BLTEclose 155.9420-day 150.9150-day 160.83200-day 160.11155.9452w high

22.0% under the 52-week high of 200.00 on 3 Feb 2026. 52-week low 102.00 on 11 Nov 2025. Last 15 sessions, 14.4% high to low

Volume 1.43× normal · the line is the 50-bar volume average

Profile

BLTE
52-week range, 55% of the way up
102200

Belite Bio, Inc. engages in the research and development of drugs. It focuses on the treatment of eye diseases involving retinal degeneration such as atrophic age-related macular degeneration and autosomal recessive Stargardt disease. It also caters to metabolic diseases such as non-alcoholic fatty liver disease, nonalcoholic steatohepatitis, type 2 diabetes, and gout. The company was founded by Yu-Hsin Lin on March 27, 2018 and is headquartered in San Diego, CA.

Employees41
IPOApr 29, 2022
Beta-1.18
ATR, 14d6.86
Rel volume1.43
Short float3.49%
Insider own1.80%
Inst own22.29%

Snapshot

6 groups

Valuation

Index-
Market Cap6.28B
Enterprise Value6.00B
Income-102.36M
Sales0.00M
Book/sh19.28
Cash/sh6.95
Dividend Est.-
Dividend TTM-
Dividend Ex-Date-
Dividend Gr. 3/5Y- -
Payout-
Employees41
IPOApr 29, 2022

Ratios

P/E-
Forward P/E82.07
PEG-
P/S-
P/B8.09
P/C22.44
P/FCF-
EV/EBITDA-
EV/Sales-
Quick Ratio50.02
Current Ratio50.02
Debt/Eq0.00
LT Debt/Eq0.00
Option/ShortYes / Yes

Earnings

EPS (ttm)-2.73
EPS next Y1.90
EPS next Q-0.79
EPS this Y-37.69%
EPS next Y159.74%
EPS next 5Y-
EPS past 3/5Y-54.04% -549.64%
Sales past 3/5Y- -
EPS Y/Y TTM-76.46%
Sales Y/Y TTM-
EPS Q/Q-41.19%
Sales Q/Q-
EarningsNov 12 AMC
EPS/Sales Surpr.9.89% -

Ownership

Insider Own1.80%
Insider Trans-20.69%
Inst Own22.29%
Inst Trans0.69%
ROA-21.60%
ROE-22.10%
ROIC-13.28%
Gross Margin-
Oper. Margin-
Profit Margin-
SMA203.33%
SMA50-3.04%
SMA200-2.60%
Trades-

Technical

Shs Outstand40.27M
Shs Float39.55M
Short Float3.49%
Short Ratio7.61
Short Interest1.38M
52W High200.00 -22.03%
52W Low102.00 52.88%
Volatility6.01% 4.58%
ATR (14)6.86
RSI (14)51.90
Beta-1.18
Rel Volume1.43
Avg Volume181.34K
Volume260,062

Performance

Perf Week1.25%
Perf Month2.68%
Perf Quarter-6.22%
Perf Half Y1.58%
Perf YTD-2.51%
Perf Year47.45%
Perf 3Y296.39%
Perf 5Y-
Perf 10Y-
Recom1.00
Target Price227.44
Prev Close156.52
Price155.94
Change %-0.37%

Analyst ratings

latest 10 of 11
DateActionAnalystRating changeTargetImplied
Sep 04, 2026InitiatedCCanaccord GenuityBuy$303+94.3%
Jan 26, 2026InitiatedBBofA SecuritiesBuy$195+25.0%
Jan 06, 2026InitiatedMMorgan StanleyOverweight$191+22.5%
Dec 02, 2025UpgradeMMizuhoNeutral → Outperform$194+24.4%
Nov 24, 2025ResumedCCantor FitzgeraldOverweight$154-1.2%
Nov 20, 2025InitiatedMMizuhoNeutral$105-32.7%
Dec 14, 2023InitiatedMMaxim GroupBuy$60-61.5%
Jul 28, 2023InitiatedCCantor FitzgeraldOverweight$43-72.4%
Jul 26, 2023InitiatedSSVB SecuritiesOutperform$25-84.0%
Aug 01, 2022InitiatedHH.C. WainwrightBuy$58-62.8%

Peers

Mkt cap
TickerCompanyMkt cap
KODKodiak Sciences Inc6.87B
OCGNOcugen Inc325.87M
ANNXAnnexon Inc794.34M
OCULOcular Therapeutix Inc1.47B
IRDOpus Genetics Inc358.58M
EYPTEyePoint Inc30.74M
REGNRegeneron Pharmaceuticals Inc99.23B
OCSOculis Holding AG469.78M
MGTXMeiraGTx Holdings plc929.69M
RGNXRegenxbio Inc560.06M

Insider trading

latest 14 of 38
InsiderRelationshipDateTransactionCostSharesValueTotal heldForm
Scholl Hendrik PeterChief Medical OfficerOct 01 '26Sale165.3250082,65914,500Oct 05 07:27 PM
Hendrik Peter SchollOfficerOct 01 '26Proposed Sale169.824,000679,280Oct 01 06:04 PM
Lin Yu-HsinChief Executive OfficerSep 04 '26Sale187.7174,43513,972,06396,134Sep 09 07:39 PM
Lin Yu-HsinChief Executive OfficerSep 08 '26Sale196.5626,0005,110,48670,134Sep 09 07:39 PM
Chuang Hao-YuanChief Financial OfficerSep 04 '26Sale187.6449,4339,275,38944,000Sep 09 07:38 PM
Chuang Hao-YuanChief Financial OfficerSep 08 '26Sale196.4217,9623,528,13926,038Sep 09 07:38 PM
Chuang Hao-YuanChief Financial OfficerAug 12 '26Sale180.3536766,18793,433Aug 14 06:10 AM
Lin Yu-HsinChief Executive OfficerAug 12 '26Sale180.3536565,827170,569Aug 14 06:10 AM
Yu-Hsin LinCEO, ChairmanAug 12 '26Proposed Sale177.58126,80022,517,144Aug 12 05:13 PM
Hao-Yuan ChuangOfficer, DirectorAug 12 '26Proposed Sale177.5893,80016,657,004Aug 12 05:12 PM
Scholl Hendrik PeterChief Medical OfficerJun 18 '26Sale145.2410,0001,452,43515,000Jun 22 06:05 AM
Dr. Hendrick P. SchollAffiliateJun 18 '26Proposed Sale148.3410,0001,483,400Jun 18 04:27 PM
Scholl Hendrik PeterChief Medical OfficerJun 16 '26Sale140.5710,0001,405,72925,000Jun 17 06:03 AM
Dr. Hendrick P. SchollAffiliateJun 16 '26Proposed Sale144.2410,0001,442,400Jun 16 07:10 PM

Held by

AUM
TickerCompanyAUM
SPEMState Street SPDR Portfolio Emerging Markets ETFAUM: 16.35B
APIEActivePassive International Equity ETFAUM: 1.13B
ONEQFidelity Nasdaq Composite Index ETFAUM: 10.35B
GXCState Street SPDR S&P China ETFAUM: 441.93M
BBCVirtus Biotech Clinical Trials ETFAUM: 31.26M
EHLSEven Herd Long Short ETFAUM: 53.35M
MSSMMorgan Stanley Pathway Small-Mid Cap Equity ETFAUM: 705.72M
TNXTT. Rowe Price Innovation Leaders ETFAUM: 18.62M

News

latest 14 of 200
  • Belite Bio's Pre-Launch Spending Faces Scrutiny As February FDA Decision On Tinlaraban Nears (Earnings Whispers) -7.03%
  • Belite Bio to Host Webcast on November 12, 2026, to Discuss Third Quarter 2026 Financial Results (GlobeNewswire)
  • Belite Bio Announces Uplisting to the Nasdaq Global Select Market (GlobeNewswire)
  • Belite Bio Announces Multi-Market Submission of Marketing Authorization Applications Via the Access Consortium Pathway for Tinlarebant for the Treatment of Stargardt Disease Type 1 (GlobeNewswire)
  • Belite Bio Announces Oral Presentations at Two Upcoming Medical Conferences (GlobeNewswire)
  • Belite Bio Announces Oral Presentations at Two Upcoming Medical Conferences (GlobeNewswire)
  • Belite Bio, Inc. Sponsored ADR (BLTE)'s Technical Outlook is Bright After Key Golden Cross (Quartz)
  • Belite Bio Announces Submission of New Drug Application to the Ministry of Health, Labour, and Welfare in Japan under the Sakigake Designation System for Tinlarebant for the Treatment of Stargardt Disease Type 1 (GlobeNewswire)
  • UiPath downgraded, Shell upgraded: Wall Street's top analyst calls (The Fly) +13.16%
  • Belite Bio to Participate in Four Upcoming Investor Conferences (GlobeNewswire)
  • Belite Bio to Host Virtual Commercial Day on September 2, 2026 (GlobeNewswire)
  • Belite Bio Announces Oral Presentations at Two Upcoming Medical Conferences (GlobeNewswire)
  • Belite Bio Inc (BLTE) (Q2 2026) Earnings Call Highlights: FDA Priority Review and Strong Cash ... (GuruFocus.com)
  • Belite Bio Reports Unaudited Second Quarter 2026 Financial Results and Provides a Corporate Update (GlobeNewswire) -7.07%

Quarterly earnings

actual against estimate
PeriodReportedEPS actEPS estEPS repSales actSales estAnalysts
2026Q32026-11-12--0.786--0.009
2026Q22026-08-13-0.700-0.777-0.7000.000.007
2026Q12026-05-20-0.340-0.635-0.6760.000.008
2025Q42026-03-02-0.380-0.546-0.6990.000.008
2025Q32025-11-10-0.650-0.488-0.6530.000.004
2025Q22025-08-11-0.500-0.410-0.5010.000.005
2025Q12025-05-14-0.450-0.352-0.4450.000.005
2024Q42025-03-17-0.320-0.308-0.3210.000.005
2024Q32024-11-12-0.280-0.288-0.2830.000.005
2024Q22024-08-09-0.310-0.256-0.3130.000.005
2024Q12024-05-14-0.270-0.285-0.2650.000.004
2023Q42024-03-12-0.250-0.300-0.2470.000.005
2023Q32023-11-14-0.400-0.320-0.4020.000.004
2023Q22023-08-09-0.260-0.298-0.2640.000.004
2023Q12023-05-11-0.330-0.200-0.3280.000.002
2022Q42023-03-31-0.370-0.120-0.00-1

Annual earnings

PeriodEPS actEPS estEPS repSales actSales est
2022FY-0.630-0.420-0.6330.000.00
2023FY-1.190-1.288-1.1900.000.00
2024FY-1.180-1.172-1.1840.000.00
2025FY-2.310-2.184-2.3100.000.00
2026FY--3.181--0.00
2027FY-1.900--274.22
2028FY-6.175--543.02
2029FY-15.668--1,161
2030FY-25.128--1,828

Estimate revisions

last 14 periods
PeriodTypeDateEstimatesUpDownMeanLowHigh
2026Q3S2026-09-038000.000.000.00
2026Q3S2026-08-137000.000.000.00
2026Q3S2026-05-207000.000.000.00
2026Q3S2026-05-046000.000.000.00
2026Q3S2026-03-035000.000.000.00
2026Q3S2026-03-024000.000.000.00
2026Q3S2025-11-284000.000.000.00
2026Q3S2025-11-213000.000.000.00
2026Q3S2025-11-112000.000.000.00
2026Q3S2025-11-101000.000.000.00
2026Q3S2025-11-091000.000.000.00
2026Q3S2025-11-081000.000.000.00
2026Q3S2025-11-071000.000.000.00
2026Q3S2025-11-061000.000.000.00

Estimate history

EPS, annual0-0.401-0.633-1.19-1.184-2.314-2.7348
Period202020212022202320242025TTM
EPS, quarterly-0.313-0.283-0.321-0.445-0.501-0.653-0.699-0.676-0.707
PeriodQ2 '24Q3 '24Q4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26Q2 '26
Sales, annual0000000
Period202020212022202320242025TTM
Sales, quarterly000000000
PeriodQ2 '24Q3 '24Q4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26Q2 '26
Shares, annual24.09524.09524.89929.14931.82739.3440.272
Period202020212022202320242025MRQ
Shares, quarterly30.61230.87931.82732.54532.59934.89139.3440.08540.272
PeriodQ2 '24Q3 '24Q4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26Q2 '26

Income statement, annual

Currency USD, millions
MetricTTM2025FY2024FY2023FY2022FY2021FY2020FY
Total Revenue0.000.000.000.000.000.000.00
Cost of Goods Sold Incl. D&A0.000.460.450.400.200.030.02
Gross Profit0.00-0.46-0.45-0.40-0.20-0.03-0.02
Selling, General and Administrative Excl. Other118.2283.7439.5531.2712.629.775.73
Research and Development58.8145.3829.9424.848.877.423.69
Other Operating Expense0.000.000.000.000.000.000.00
Operating Income-118.22-84.21-40.00-31.67-12.82-9.80-5.74
Interest Expense-0.000.020.030.020.000.02
Unusual Expense0.000.000.000.000.000.000.00
Net Income Before Taxes-102.31-77.61-36.14-31.62-12.65-9.67-5.75
Income Taxes0.060.000.010.010.000.000.00
Consolidated Net Income-102.36-77.61-36.14-31.63-12.65-9.67-5.75
Net Income From Continuing Operations-102.36-77.61-36.14-31.63-12.65-9.67-5.75
Net Income-102.36-77.61-36.14-31.63-12.65-9.67-5.75
EPS (Recurring)-2.55-2.31-1.18-1.19-0.63-0.40-0.24
EPS (Basic, Before Extraordinaries)-2.73-2.31-1.18-1.19-0.63-0.40-0.00
EPS (Diluted)-2.73-2.31-1.18-1.19-0.63-0.40-0.00
EBITDA--83.74-39.55-31.27-12.62-9.77-5.73
Non-Operating Income (Expense)9.746.603.880.070.190.130.01
Other After Tax Adjustments0.000.000.000.000.000.000.00
Stock Option Compensation Expense-38.927.103.021.171.530.99
Shares Outstanding40.2739.3431.8329.1524.9024.1024.10
Market Capitalization6,280.036,280.031,948.481,262.66726.35726.35-

Income statement, quarterly

Currency USD, millions
Metric2026Q22026Q12025Q42025Q32025Q22025Q12024Q42024Q3
Total Revenue0.000.000.000.000.000.000.000.00
Cost of Goods Sold Incl. D&A0.000.000.120.350.000.000.000.00
Gross Profit0.000.00-0.12-0.350.000.000.000.00
Selling, General and Administrative Excl. Other34.9132.6827.9622.6717.6015.5211.469.74
Research and Development18.2115.6614.6210.3111.059.407.256.84
Other Operating Expense0.000.000.000.000.000.000.000.00
Operating Income-34.91-32.68-28.08-23.02-17.60-15.52-11.46-9.74
Interest Expense--0.000.000.000.000.000.00
Unusual Expense0.000.000.000.000.000.000.000.00
Net Income Before Taxes-28.36-26.94-25.32-21.69-16.32-14.28-10.10-8.68
Income Taxes0.060.000.000.000.000.000.000.00
Consolidated Net Income-28.41-26.94-25.32-21.69-16.32-14.28-10.10-8.68
Net Income From Continuing Operations-28.41-26.94-25.32-21.69-16.32-14.28-10.10-8.68
Net Income-28.41-26.94-25.32-21.69-16.32-14.28-10.10-8.68
EPS (Recurring)-0.71-0.68-0.70-0.65-0.50-0.44-0.32-0.28
EPS (Basic, Before Extraordinaries)-0.71-0.68-0.70-0.65-0.50-0.45-0.32-0.28
EPS (Diluted)-0.71-0.68-0.70-0.65-0.50-0.45-0.32-0.28
EBITDA---27.96-22.67-17.60-15.52-11.46-9.74
Non-Operating Income (Expense)6.555.752.751.331.281.241.361.06
Other After Tax Adjustments0.000.000.000.000.000.000.000.00
Stock Option Compensation Expense5.3613.2011.71-----
Shares Outstanding40.2740.0939.3434.8932.6032.5431.8330.88
Market Capitalization6,280.036,272.375,581.162,412.351,877.842,107.561,948.481,435.11

Balance sheet, annual

Currency USD, millions
Metric2025FY2024FY2023FY2022FY2021FY2020FY
Cash & Short Term Investments492.42145.1588.1642.0917.3425.62
Short Term Receivables0.720.590.870.020.020.04
Inventories0.000.000.000.000.000.00
Other Current Assets1.131.330.920.700.060.01
Total Current Assets494.27147.0789.9442.8117.4325.67
Net Property, Plant & Equipment0.780.961.301.350.090.07
Total Investments and Advances280.170.000.000.000.000.00
Intangible Assets0.020.030.000.000.000.00
Other Assets5.324.063.400.120.820.01
Total Assets780.56152.1394.6444.2718.3525.74
Short Term Debt Incl. Current Port. of LT Debt0.240.280.310.200.000.00
Accounts Payable0.000.000.000.000.000.00
Other Current Liabilities9.645.773.331.911.640.97
Total Current Liabilities9.886.053.632.101.640.97
Long Term Debt0.190.260.580.6731.8131.81
Provision for Risks Charges0.000.000.000.000.000.00
Other Liabilities0.000.000.000.000.000.00
Total Liabilities10.076.314.212.7733.4432.78
Non-Equity Reserves0.000.000.000.000.000.00
Preferred Stock - Carrying Value0.000.000.000.000.000.00
Common Equity770.49145.8290.4341.50-15.09-7.04
Total Shareholders Equity770.49145.8290.4341.50-15.09-7.04
Accumulated Minority Interest0.000.000.000.000.000.00
Total Equity770.49145.8290.4341.50-15.09-7.04
Total Liabilities & Stockholders Equity780.56152.1394.6444.2718.3525.74
Book Value Per Share19.594.583.101.67-0.63-0.29
Tangible Book Value Per Share19.584.583.101.67-0.63-0.29
Full-Time Employees4125201612-
Price to Book Ratio8.0917.3723.92---
Return on Assets-16.64-29.29-45.54-40.40-43.85-
Return on Equity-16.94-30.60-47.95-95.79--
Return on Invested Capital-10.07-24.74-34.76-29.99-57.84-23.23
Quick Ratio50.0224.3124.7620.3510.6626.41
Current Ratio50.0224.3124.7620.3510.6626.41

Cash flow, annual

Currency USD, millions
MetricTTM2025FY2024FY2023FY2022FY2021FY2020FY
Net Income--77.61-36.14-31.63-12.65-9.67-5.75
Depreciation-0.460.450.400.200.030.02
Deferred Taxes & Investment Tax Credit-0.000.000.000.000.000.00
Other Funds (Non Cash)-37.615.333.821.481.521.36
Funds from Operations--39.54-30.37-27.41-10.97-8.11-4.37
Extraordinary Item-0.000.000.000.000.000.00
Changes in Working Capital-2.551.13-2.43-0.490.64-0.07
Cash from Operating Activities--36.99-29.23-29.84-11.46-7.47-4.44
Capital Expenditures--0.07-0.15-0.06-0.39-0.07-0.02
Net Assets From Acquisitions-0.000.000.000.000.000.00
Sale of Fixed Assets and Businesses-0.000.000.000.000.020.00
Purchase or Sale of Investments--304.93-110.420.000.000.000.00
Purchase of Investments--451.99-188.260.000.000.000.00
Sale Or Maturity of Investments-147.0677.840.000.000.000.00
Other Uses--0.110.000.000.000.000.00
Other Sources-0.000.000.000.000.000.00
Cash from Investing Activities--305.11-110.57-0.06-0.39-0.06-0.02
Cash Dividends Paid-0.000.000.000.000.000.00
Preferred Dividends (Cash Flow)-0.000.000.000.000.000.00
Change in Capital Stock-663.2383.7777.1936.96-0.5830.38
Repurchase of Common Pref Stock-0.000.000.000.000.000.00
Sale of Common Pref Stock-663.2383.7777.1936.96-0.5830.38
Proceedsfrom Stock Options-552.3942.0576.8436.96-0.8130.29
Issuance or Reduction of Debt, Net-0.000.000.000.000.00-2.32
Change in Long Term Debt-0.000.000.000.000.000.00
Issuance of Long Term Debt-0.000.000.000.000.000.00
Reduction of Long Term Debt-0.000.000.000.000.000.00
Net Financing Active Other Cash Flow-0.00-0.18-1.230.000.000.00
Other Financing Activities Uses-0.00-0.18-1.230.000.000.00
Cash from Financing Activities-663.2383.5975.9636.96-0.5828.06
Exchange Rate Effect-0.12-0.270.01-0.37-0.160.00
Net Change in Cash-321.25-56.4846.0724.75-8.2723.60
Free Cash Flow--37.06-29.35-29.90-11.85-7.55-4.46

Balance sheet, quarterly

Currency USD, millions
Metric2026Q22026Q12025Q42025Q32025Q22025Q1
Cash & Short Term Investments279.90276.40492.42275.61149.20157.40
Short Term Receivables--0.720.020.000.00
Inventories--0.000.000.000.00
Other Current Assets221.70245.461.131.581.771.89
Total Current Assets501.60521.86494.27277.21150.97159.29
Net Property, Plant & Equipment--0.780.830.000.00
Total Investments and Advances--280.170.000.000.00
Intangible Assets--0.020.02--
Other Assets289.98289.415.324.335.444.91
Total Assets791.58811.27780.56282.39156.41164.20
Short Term Debt Incl. Current Port. of LT Debt--0.240.270.000.00
Accounts Payable0.000.000.000.000.000.00
Other Current Liabilities0.000.009.647.800.000.00
Total Current Liabilities0.000.009.888.070.000.00
Long Term Debt--0.190.240.000.00
Provision for Risks Charges0.000.000.000.000.000.00
Other Liabilities14.9515.480.000.006.526.13
Total Liabilities14.9515.4810.078.316.526.13
Non-Equity Reserves--0.000.000.000.00
Preferred Stock - Carrying Value0.000.000.000.000.000.00
Common Equity776.64795.79770.49274.08149.88158.07
Total Shareholders Equity776.64795.79770.49274.08149.88158.07
Accumulated Minority Interest--0.000.000.000.00
Total Equity776.64795.79770.49274.08149.88158.07
Total Liabilities & Stockholders Equity791.58811.27780.56282.39156.41164.20
Book Value Per Share19.2819.8519.597.864.604.86
Tangible Book Value Per Share19.2819.8519.587.854.604.86
Full-Time Employees--41---
Price to Book Ratio8.098.1420.3616.0911.8814.45
Return on Assets-21.60-18.51-16.64-31.33-35.93-32.07
Return on Equity-22.10-18.93-16.94-32.30-37.34-33.43
Return on Invested Capital---3.29-7.91-10.89-9.03
Quick Ratio--50.0234.37--
Current Ratio--50.0234.37--

Cash flow, quarterly

Currency USD, millions
Metric2026Q22026Q12025Q42025Q32025Q22025Q1
Net Income---25.32---
Depreciation--0.12---
Other Funds (Non Cash)--13.56---
Funds from Operations---11.65---
Extraordinary Item--0.00---
Changes in Working Capital--1.26---
Cash from Operating Activities---10.38---
Capital Expenditures---0.07---
Net Assets From Acquisitions--0.00---
Sale of Fixed Assets and Businesses--0.00---
Purchase or Sale of Investments---303.56---
Purchase of Investments---356.23---
Sale Or Maturity of Investments--52.68---
Other Uses---0.11---
Other Sources--0.00---
Cash from Investing Activities---303.73---
Cash Dividends Paid--0.00---
Preferred Dividends (Cash Flow)--0.00---
Change in Capital Stock--510.12---
Repurchase of Common Pref Stock--0.00---
Sale of Common Pref Stock--510.12---
Proceedsfrom Stock Options--406.10---
Issuance or Reduction of Debt, Net--0.00---
Change in Long Term Debt--0.00---
Issuance of Long Term Debt--0.00---
Reduction of Long Term Debt--0.00---
Net Financing Active Other Cash Flow--0.00---
Other Financing Activities Uses--0.00---
Cash from Financing Activities--510.12---
Exchange Rate Effect---0.10---
Net Change in Cash--195.90---
Free Cash Flow---10.46---

Revenue breakdown

Revenue split-

Short interest

shares short against float, oldest to newest
SettlementOf floatShares shortFloatAvg volume
2026-10-303.49%1.4M39.6M178.29K
2026-10-153.20%1.3M39.6M183.77K
2026-09-302.67%1.1M39.6M185.23K
2026-09-152.66%1.1M39.6M202.19K
2026-08-312.66%1.0M39.5M196.82K
2026-08-142.82%1.1M39.5M214.07K
2026-07-312.87%1.1M39.5M200.94K
2026-07-153.32%1.3M39.6M190.76K
2026-06-303.32%1.3M39.6M186.68K
2026-06-153.35%1.3M39.6M174.18K
2026-05-293.04%1.2M39.6M165.08K
2026-05-153.01%1.2M39.6M155.04K
2026-04-303.11%1.2M39.6M169.59K
2026-04-152.81%1.1M39.6M186.88K
2026-03-312.68%1.0M39.0M209.11K
2026-03-132.54%1.0M39.0M213.88K
2026-02-272.03%0.8M39.0M245.47K
2026-02-131.97%0.7M34.6M248.48K
2026-01-30-0.6M-232.63K
2026-01-15-0.4M-210.80K

Option chain

expiry 2026-11-20
TypeStrikeBidAskLastIVOpen intVolumeDeltaThetaVega
call10053.5058.500.002.3560.000.000.890-0.7450.046
call10548.5053.500.002.1520.000.000.880-0.7260.048
call11044.0048.9034.001.9552.000.000.870-0.7050.051
call11539.0043.900.001.7660.000.000.858-0.6820.055
call12034.0039.000.001.6830.000.000.844-0.6560.058
call12529.5034.000.001.4960.000.000.828-0.6280.062
call13025.0029.500.001.3960.000.000.809-0.5950.066
call13520.5025.000.001.2820.000.000.785-0.5570.071
call14016.0020.800.001.1280.000.000.755-0.5130.076
call14512.0016.800.001.0610.000.000.700-0.5260.084
call1508.6013.400.001.1160.000.000.627-0.5570.092
call1555.6010.400.001.0740.000.000.549-0.5640.096
call1603.107.900.000.9940.000.000.467-0.5500.096
call1651.656.500.001.0410.000.000.395-0.5500.093
call1701.004.900.001.0420.000.000.327-0.5200.088
call1750.004.900.001.1900.000.000.300-0.5730.084
call1800.004.901.501.3262.000.000.278-0.6150.081
call1850.004.900.001.4400.000.000.259-0.6440.079
call1900.004.900.351.5580.003.000.245-0.6770.076
call1950.004.900.001.6700.000.000.234-0.7060.074
call2000.054.900.041.7763010.000.224-0.7330.073
call2100.004.900.001.9740.000.000.208-0.7800.070
call2200.004.900.002.1550.000.000.196-0.8210.067
call2300.004.900.002.3220.000.000.186-0.8570.065
put1000.004.900.102.8492.000.00-0.110-0.7330.046
put1050.004.900.002.6170.000.00-0.120-0.7140.048
put1100.004.900.002.3930.000.00-0.130-0.6930.051
put1150.004.900.002.1770.000.00-0.142-0.6690.055
put1200.004.900.001.9680.000.00-0.156-0.6430.058
put1250.004.900.001.7630.000.00-0.172-0.6130.062
put1300.004.900.651.5630.003.00-0.191-0.5800.066
put1350.004.902.501.3641.000.00-0.215-0.5420.071
put1400.004.504.751.1585.000.00-0.246-0.4950.076
put1450.655.504.701.0823.000.00-0.301-0.5140.085
put1502.507.000.001.0280.000.00-0.372-0.5320.092
put1554.509.300.001.0310.000.00-0.451-0.5490.096
put1607.0011.800.000.9620.000.00-0.532-0.5400.096
put16510.5015.300.001.0300.000.00-0.604-0.5370.094
put17014.0018.400.000.9860.000.00-0.673-0.5010.088
put17518.0022.400.001.0080.000.00-0.703-0.5450.084
put18022.5027.300.001.0820.000.00-0.724-0.5870.081
put18527.0031.400.001.1110.000.00-0.741-0.6240.079
put19032.0036.400.001.2190.000.00-0.755-0.6560.076
put19537.0041.500.001.3370.000.00-0.766-0.6850.074
put20041.5046.500.001.4350.000.00-0.776-0.7110.073
put21051.5056.5066.501.6171.000.00-0.792-0.7570.070
put22061.5066.5076.501.6850.000.00-0.804-0.7970.067
put23071.5076.500.001.9400.000.00-0.814-0.8320.065

Latest SEC filings

30
FiledFormDescriptionPeriodLink
2026-10-304Statement of changes in beneficial ownership of securities2026-10-29SEC
2026-10-304Statement of changes in beneficial ownership of securities2026-10-29SEC
2026-10-304Statement of changes in beneficial ownership of securities2026-09-24SEC
2026-10-196-KCurrent report of foreign issuer pursuant to Rules 13a-16 and 15d-162026-10-19SEC
2026-10-054Statement of changes in beneficial ownership of securities2026-10-01SEC
2026-10-01144Filing for proposed sale of securities under Rule 144.SEC
2026-09-094Statement of changes in beneficial ownership of securities2026-09-04SEC
2026-09-094Statement of changes in beneficial ownership of securities2026-09-04SEC
2026-09-086-KCurrent report of foreign issuer pursuant to Rules 13a-16 and 15d-162026-09-08SEC
2026-08-144Statement of changes in beneficial ownership of securities2026-08-12SEC
2026-08-144Statement of changes in beneficial ownership of securities2026-08-12SEC
2026-08-136-KCurrent report of foreign issuer pursuant to Rules 13a-16 and 15d-162026-08-12SEC
2026-08-12144Filing for proposed sale of securities under Rule 144.SEC
2026-08-12144Filing for proposed sale of securities under Rule 144.SEC
2026-08-116-KCurrent report of foreign issuer pursuant to Rules 13a-16 and 15d-162026-08-11SEC
2026-06-224Statement of changes in beneficial ownership of securities2026-06-18SEC
2026-06-18144Filing for proposed sale of securities under Rule 144.SEC
2026-06-174Statement of changes in beneficial ownership of securities2026-06-16SEC
2026-06-16144Filing for proposed sale of securities under Rule 144.SEC
2026-06-156-KCurrent report of foreign issuer pursuant to Rules 13a-16 and 15d-162026-06-12SEC
2026-05-206-KCurrent report of foreign issuer pursuant to Rules 13a-16 and 15d-162026-05-20SEC
2026-05-14SCHEDULE 13G/ASEC
2026-05-084Statement of changes in beneficial ownership of securities2026-05-07SEC
2026-05-074Statement of changes in beneficial ownership of securities2026-05-06SEC
2026-05-064Statement of changes in beneficial ownership of securities2026-05-05SEC
2026-05-054Statement of changes in beneficial ownership of securities2026-05-04SEC
2026-05-044Statement of changes in beneficial ownership of securities2026-05-01SEC
2026-05-014Statement of changes in beneficial ownership of securities2026-04-30SEC
2026-04-304Statement of changes in beneficial ownership of securities2026-04-29SEC
2026-04-294Statement of changes in beneficial ownership of securities2026-04-28SEC

Insider activity by month

MonthBoughtBuysSoldSells
2026-110000
2026-100082.66K1
2026-090031.89M4
2026-0800132.01K2
2026-070000
2026-06002.86M2
2026-0500722.79K5
2026-04004.94M15
2026-030000
2026-020000
2026-010000
2025-120000
2025-110000

Institutional holders

Manager% owned
Darwin Global Management, Ltd.7.68%
Paradigm Biocapital Advisors LP3.08%
RTW INVESTMENTS, LP1.78%
MILLENNIUM MANAGEMENT LLC1.23%
MAVERICK CAPITAL LTD0.99%
EVENTIDE ASSET MANAGEMENT, LLC0.97%
DEERFIELD MANAGEMENT COMPANY, L.P.0.89%
Holocene Advisors, LP0.63%
Logos Global Management LP0.62%
MORGAN STANLEY0.59%

Funds

Fund% owned
T. Rowe Price Health Sciences Fund, Inc.0.20%
ALGER SMALL CAP FOCUS FUND0.15%
T. Rowe Price Health Sciences Portfolio0.01%
ActivePassive International Equity ETF0.01%
Virtus Biotech Clinical Trials Etf0.01%
Even Herd Long Short ETF0.00%
ALGER HEALTH SCIENCES FUND0.00%
ALGER SMALL CAP GROWTH FUND0.00%
Alger Small Cap Growth Portfolio0.00%
Morgan Stanley Pathway Small-Mid Cap Equity ETF0.00%

OakChart. BLTE. Cached 15 minutes.